Codis Emerges as New CDMO Powerhouse with Global Spray Drying Capabilities

In a significant development for the pharmaceutical manufacturing landscape, Codis has made its debut as a new contract development and manufacturing organization (CDMO) with an impressive global footprint. The company, formed through the merger of U.S.-based Particle Dynamics and a former EuroAPI facility in the UK, positions itself as a leader in spray drying technology and finished dose manufacturing.

Strategic Merger Creates Formidable CDMO Player

Codis emerges from the fusion of Particle Dynamics' existing operations in St. Louis and Seymour, Indiana, with the recently acquired spray drying facility in Haverhill, UK. This strategic move has resulted in a CDMO with a combined annual spray drying capacity exceeding 5,000 metric tons, which the company claims is among the largest worldwide.

Nicolas Fortin, Chief Executive of Codis, emphasized the company's strong foundation, stating, "Codis is built on a foundation of scale, quality, and global reach. With a total of 40,000 square meters of manufacturing space, three GMP facilities and with 7 regulatory approvals achieved, we are uniquely positioned to help pharmaceutical innovators accelerate therapies from development to market."

Comprehensive Service Offering and Specialized Capabilities

Beyond its substantial spray drying capacity, Codis has positioned itself to provide a wide array of services to the pharmaceutical, consumer health, and over-the-counter markets. The company's capabilities include:

• Commercial-scale production of amorphous solid dispersions
• Particle engineering
• Finished dose manufacturing

Notably, the Haverhill facility brings with it a legacy of expertise, being one of the world's primary producers of sevelamer, a medication used to treat hyperphosphatemia.

Industry Context and Market Positioning

Codis joins a wave of new CDMOs entering the market in 2025, reflecting ongoing dynamism in the pharmaceutical manufacturing sector. This debut follows other recent entrants such as Rezon Bio in Europe, Meribel Pharma Solutions in the UK, and Artis BioSolutions in the United States, each carving out specialized niches in the contract manufacturing space.

The formation of Codis also highlights the ongoing restructuring efforts within the pharmaceutical industry. The Haverhill facility, acquired from EuroAPI, was divested as part of EuroAPI's FOCUS-27 plan, which aims to streamline operations and reduce workforce by approximately 550 jobs by 2027.

With its robust technological capabilities and global presence, Codis appears well-positioned to compete in the increasingly sophisticated and demanding world of pharmaceutical contract manufacturing, offering critical support to drug developers seeking to bring innovative therapies to market efficiently.